Olanzapine leads to nonalcoholic fatty liver disease through the apolipoprotein A5 pathway

Li, R., Zhu, W., Huang, P., Yang, Y., Luo, F., Dai, W., Shen, L., Pei, W., & Huang, X. (2021). Olanzapine leads to nonalcoholic fatty liver disease through the apolipoprotein A5 pathway. Biomedicine & Pharmacotherapy, 141, 111803. https://doi.org/10.1016/j.biopha.2021.111803
Authors:
Rong Li
Wenqiang Zhu
Piaopiao Huang
Yang Yang
Fei Luo
Wen Dai
Li Shen
Wenjing Pei
Xiansheng Huang
Affiliated Authors:
Wen Dai
Columbia Affiliation:
Author Keywords:
apolipoprotein a5
nonalcoholic fatty liver disease
olanzapine
sortilin
triglyceride
elink
Publication Type:
Article
Unique ID:
10.1016/j.biopha.2021.111803
PMID:
34146854
DOI:
10.1016/j.biopha.2021.111803
Journal:
Biomedicine and Pharmacotherapy
Publication Date:
Data Source:
Scopus
Source Link:
View Scopus Record

Record Created: